News Article

Handy-LC™Makes Use of a Suite of Microfluidic Components for Portable Low Pressure Liquid Chromatography
Date: Mar 01, 2012
Source:

Featured firm in this article: SFC Fluidics Inc of Fayetteville, AR



FAYETTEVILLE, AR, March 2012 - SFC Fluidics, LLC, a microfluidic device development company, has created a portable low-pressure liquid chromatography system (LPLC). Branded 'Handy-LCâ„¢, the device exemplifies the promise of total device miniaturization. Roughly the size of a small shoebox, Handy-LC can be used anywhere to conduct real-time separation of complex samples and is perfect for LPLC applications, such as affinity chromatography or size exclusion chromatography. Handy-LC is ideal for quality/activity assurance prior to vaccine or antibody administration in a resource-constrained environment, inline quality control during biomacromolecule production and for biopharmaceutical discovery and development. "Handy-LC will eliminate the need to stabilize samples and transport them to a laboratory for analysis/purification and will therefore increase efficiency and lower total costs in production and research environments," said Dr. Sai Kumar, the company's VP of R&D. "The small size and portability of this device means that it can be used when and where needed."
Handy-LC is the latest in a series of miniaturized analytical devices developed by SFC Fluidics that incorporate the company's patented microfluidic components: ePump® and QuickConnect™(both of which are available on our website as either OEM modules or as standalone components). The ePump is capable of delivering a precise pulseless flow rate that spans four orders of magnitude (20 nL/min to 200 uL/min) against back pressures up to 100 psi. The QuickConnect connectors are rated at 100 psi and allow for instantaneous snap together assembly of modular components. Handy-LC is testament to the practical realization of miniaturized devices enabled by the company's unique microfluidic components.
SFC Fluidics is developing a number of miniaturized analytical and diagnostic platforms using its suite of patented and patents-pending microfluidic and detection technologies. It will be a company to watch in the new era of personalized medicine and cost-effective health care